Published in Vaccine Weekly, April 14th, 2010
of its vaccine for Parkinson's disease. The vaccine, known as PD01, has undergone numerous preclinical tests which have confirmed its principle of action ("Proof of Concept"). The company is now starting to prepare for clinical trials of the vaccine which are planned to commence at the beginning of 2011. Due to a completely innovative effect approach this vaccine could for the first time offer a chance of treating the causes of Parkinson's disease. The basis of PD01 is the company's AFFITOM® technology, on which two vaccines for Alzheimer's disease are based that have already successfully...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2010-04-14)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.